Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 3/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2202944 | 0.86 | CXCR4 (0.40) | CXCR4BCHE | |
| SCHEMBL1638006 | 0.82 | CXCR4 (0.60) | CXCR4LTA4HPPARGPPARADRD2 | |
| SCHEMBL12426479 | 0.82 | CXCR4 (0.41) | CXCR4LTA4HPPARGPPARABCHE | |
| SCHEMBL12426408 | 0.81 | LTA4H (0.41) | LTA4HPPARGPPARABCHEACHE | |
| SCHEMBL2202949 | 0.80 | CXCR4 (0.38) | CXCR4 | |
| SCHEMBL2202937 | 0.80 | CXCR4 (0.38) | CXCR4 | |
| SCHEMBL12509869 | 0.80 | LTA4H (0.36) | CXCR4LTA4HPPARGPPARABCHE | |
| SCHEMBL12426453 | 0.79 | ALDH1A1 (0.39) | LTA4HPPARGBCHEACHE | |
| SCHEMBL12426518 | 0.78 | CXCR4 (0.49) | CXCR4LTA4HPPARGPPARA | |
| SCHEMBL12426462 | 0.76 | KMT2A (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977512-B2 | Amine derivative, and production method and use thereof | KUREHA CORPORATION (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977512-B2 | Amine derivative, and production method and use thereof | KUREHA CORPORATION (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20080293951-A1 | Amin Derivative, and Production Method and Use Thereof | KUREHA CORPORATION | 2008-11-27 | — | — | US | disclosed |
| US-20080293951-A1 | Amin Derivative, and Production Method and Use Thereof | KUREHA CORPORATION | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293951-A1 | Amin Derivative, and Production Method and Use Thereof | BCAT2, BCAT1, MRPL9 | CXCR4 2546/4885LTA4H 645/4885PPARG 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.